Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

6 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-09

Study Completion Date

2027-10-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen; this in turn can injure organs including the heart, lungs, and kidneys. SCD can lead to serious illness and death. Treatments such as bone marrow transplants and gene therapies can cure SCD, but they are not widely available. Current drug treatments for SCD are not always effective. This natural history study will examine how a study drug (mitapivat) affects red blood cells in people with SCD.

Objective:

To learn how mitapivat affects red blood cells in people with SCD.

Eligibility:

People with SCD who are enrolled in the parent study, NIH protocol IRB001565-H.

Design:

Procedures for this study will be done during visits already scheduled for the parent study.

Participants will have additional blood drawn during study visits. The additional amount will be about 3.5 teaspoons.

Participants will undergo a test called near infrared spectroscopy (NIRS) up to 9 times. Probes will be placed on their skin. A blood pressure cuff will be placed on their arm. The cuff will be filled with air for up to 5 minutes and then released. Participants may be asked to breathe at a certain rate or to hold their breath during these measurements. NIRS measures oxygen levels, blood flow, and the makeup of skin and muscle.

Researchers will draw additional information for this study from participants medical records.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

NCT04610866

Sickle Cell Disease Hemolytic Anemia

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels

NCT04008368

Myeloid Chimerism

RECRUITING PHASE1/PHASE2

A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders

NCT00005783

Hemoglobin SC Disease Sickle Cell Anemia

COMPLETED PHASE1

Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies

NCT05213572

Mortality in Sickle Cell Sickle Cell Cardiopulmonary Complications Sickle Cell Organ Damage +2 more

RECRUITING

Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension

NCT03572036

Pulmonary Hypertension Sickle Cell Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Description:

Subjects actively enrolled protocol AG348-C-020 (NIH protocol IRB001565-H), an industry-sponsored phase 2/3 study investigating the efficacy of mitapivat in treating sickle cell disease (SCD), will be invited to participate in this protocol simultaneously to further investigate the mechanistic effects of mitapivat. Subjects will be asked for a blood sample at study visits and undergo near infrared spectroscopy (NIRS) testing to investigate the mechanisms of action of mitapivat in subjects with SCD.

Objectives:

To evaluate the mechanisms of action of mitapivat in subjects with SCD.

Endpoints:

PRIMARY ENDPOINT DURING BLINDED PERIOD:

The percentage change in the oxygen affinity measure p50 (defined as the partial pressure of oxygen at which Hb is 50% saturated with oxygen) between baseline and the average value at 12, 24 and 52 weeks. This change will be compared between the placebo and mitapivat arms.

PRIMARY ENDPOINTS DURING OPEN LABEL EXTENSION (OLE):

* Evaluate the effect of mitapivat by comparing inter-patient and intra-patient changes between year one and year two.
* Evaluate the effects of long term use of mitapivat in patients who were randomized onto mitapivat during the first year of the study.
* Evaluate the intra-patient changes for patients who were randomized onto the placebo during the first year of the study and transition to mitapivat during year two.

SECONDARY ENDPOINTS DURING BLINDED PERIOD:

* The p50 changes will also be assessed at the individual time points of 12, 24, and 52 weeks.
* Percentage of sickled cells and time to 50% sickling (t50) under normal and hypoxic ex vivo conditions at regular time intervals on mitapivat and percentage change from baseline to the individual time points at 12, 24, and 52 weeks. This change will be compared between the placebo and mitapivat arms.
* Percentage change in intracellular reactive oxidative species (ROS) in red blood cells (RBCs) using a ROS sensitive fluorescent probe and mass spectrometry- based proteomics of RBC lysates between baseline and the individual time points at 12, 24, and 52 weeks. This change will be compared between the placebo and mitapivat arms.
* The percentage change in phosphatidylserine (PS) externalization using annexin V labeling (marker of red cell survival) by flow cytometry between baseline and the individual time points at 12, 24, and 52 weeks. This change will be compared between the placebo and mitapivat arms.
* Percentage change in muscle physiology, tissue oxygenation and blood flow using NIRS methodologies between baseline the individual time points at 12, 24, and 52 weeks. This change will be compared between the placebo and mitapivat arms.
* RBC deformability and sickling using osmotic and oxygen gradient ektacytometry

TERTIARY/EXPLORATORY ENDPOINTS DURING BLINDED PERIOD:

* Evaluate effect of mitapivat on RBC metabolomics and proteomics between baseline and various follow-up periods. This change will be compared between the placebo and mitapivat arms.
* Measurement of glycated Hb S level as a surrogate measure for red cell half-life between baseline and various follow-up periods. This change will be compared between the placebo and mitapivat arms.
* Evaluate effect of mitapivat on RBC band 3 tyrosine phosphorylation between baseline and various follow-up periods.

This change will be compared between the placebo and mitapivat arms.

* Correlation between potential exploratory biomarkers and clinical laboratory parameters.
* Evaluate change in cerebral hemodynamic measurements through magnetic resonance imaging (MRI) for cerebral blood flow, oxygen extraction fraction, and cerebral metabolic rate of oxygen consumption from baseline, at 12 and 52 weeks. This change will be compared between the placebo and mitapivat arms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Anemia Sickle Cell Thalassemia Sickle Cell Pain Hbss Hbsc Sickle Beta Thalassemia Sickle Beta Zero Thalassemia Sickle Cell Syndrome Variant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

i. Phase 3: Mitapivat 50 mg BID

No interventions assigned to this group

2

ii. Phase 3: Mitapivat 100 mg BID

No interventions assigned to this group

3

iii. Phase 3: Mitapivat Open-Label Extension Period

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All subjects enrolled at NIH meeting eligibility for the parent study (AG348-C-020) are eligible for this study.

Exclusion Criteria

Subjects that did not meet eligibility criteria to the parent protocol (AG348-C-020) will not be eligible to enroll for this study.

Subjects will be screened for implanted metal objects or devices that may be incompatible with MRI (i.e. cerebral aneurysm clip, cochlear implant, pacemaker, etc.) These subjects will be eligible to proceed with study enrollment, but will not undergo the optional MRI study.

Minimum Eligible Age

16 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No